BioSpace News Archive

TELA Bio, Inc. announced that it has appointed Doug Evans, the President and Chief Executive Officer of Lungpacer Medical Inc., and Lisa Colleran, a principal of LNC Advisors, LLC, to its board of directors effective April 20, 2020.

Revenue in the first quarter of 2020 increased 15 percent, driven by 22 percent volume growth. Strong underlying demand for key growth products was augmented by approximately $250 million of additional revenue due to increased customer buying patterns and patient prescription trends due to the COVID-19 pandemic.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two double-blind, placebo controlled animal studies in Alzheimer’s disease and Parkinson’s disease demonstrating in both diseases preclinical efficacy of ANVS401, the company’s lead compound.

Anixa Biosciences, Inc., a biotechnology company focused on the treatment, prevention, and diagnosis of cancer and infectious diseases, announced the publication of a peer-reviewed journal article in Biomarker Insights.

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that the Company will release its first quarter 2020 financial results on Wednesday, May 6, 2020 before the U.S. financial markets open.

MeridianHealth, a subsidiary of Centene Corporation, announced an initiative designed to support individuals residing in the State of Illinois that are experiencing or at risk of homelessness.

Enhanced Survival Outcomes Achieved in Patients with Wnt Activating Mutations and DKK1-high Tumors

Bausch Health Companies Inc. will release its first-quarter 2020 financial results on Thursday, May 7, 2020.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, announced the appointment of Zafar Qadir as the Company’s General Counsel.

iCAD, Inc. announced it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,562,500 shares of the Company’s common stock at $8.00 per share, pursuant to a registered direct offering.